Infectious Disease

With over 3% of the world’s population affected by chronic hepatitis B, TherVacB has the potential to address a critical unmet need for a cure.

Of the 2596 patients included in the study, the hospitalization rates were 31.5% for Omicron, 27.7% for influenza, and 81.7% for RSV.

The use of tecovirimat for monkeypox and other non-variola orthopoxvirus infections is under an expanded access IND protocol, according to the CDC.

The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.

Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

Patients hospitalized for either virus had an increased risk of death, hospital readmission, and health problems in multiple organ systems over 18 months of follow-up.

Three posters presented at ASHP Midyear 2023 delved deeper into the topic of antimicrobial stewardship programs and their impact on antibiotic resistance.

Two posters presented at ASHP Midyear 2023 looked at how the two medications differed and how clinical pharmacy services improved transitions.

The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.

The FDA approval marks an important public health milestone in the ongoing effort to empower patients to take control of their own health.

Ixchiq was approved through the FDA Accelerated Approval pathway.

In a recent Morbidity and Mortality Weekly Report (MMWR), the results of a study showed 63% of those who died from HAV had at least 1 documented preexisting indication for vaccination.

By way of natural immunity, vaccination, and behavior change, the majority of the 30,861 documented cases and 54 deaths were confined to 2022, and the epidemic curve portrays a picture of success.

Anesthetic gases and meter dose inhalers, how we use our antibiotics, how we use our resources for infection prevention and control, and how we use plastic and food in our hospitals all add up.

Pediatric TB is an intricate challenge that demands continued attention and funding.

Isaac "Zak" Kohane, MD, PhD, the inaugural chair of Harvard Medical School's Department of Biomedical Informatics, discussed artificial intelligence during a plenary session at IDWeek 2023.

The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Stephen L. Foster, PharmD, FAPhA, FNAP, discussed the new vaccine and RSV prevalence at the National Community Pharmacists Association 2023 Convention and Expo.

Group B streptococcus is the most common cause of early- and late-onset neonatal sepsis.

Considering recent legal challenges to gender affirming and reproductive healthcare, pharmacists play an essential part to help marginalized populations have access to HIV prevention.

A new study found that more patients hospitalized with RSV needed standard flow oxygen, HFNC, NIV, and ICU admission than the patients with COVID-19 and influenza.

Based on data from an ongoing clinical trial and other studies, the R21 vaccine has been shown to have a high degree of efficacy when administered just before the high transmission season, with data showing a 75% reduction in cases of malaria in the 12 months following the 3-dose series.

A refresher on best interventions for common respiratory disorders in children.

Beyond female gender, comorbidities independently associated with C diff infection in patients diagnosed with COVID-19 included peptic ulcer disease, renal failure, weight loss, diabetes mellitus with complications, and congestive heart failure.

A study found that the 3 leading cell type therapies used to treat COVID-19 were mesenchymal stem cells or multipotent stromal cells, natural killer cells, and mononuclear cells.

Investigators saw there was a significant difference of lower treatment initiation in people younger than 30 years old, females, Hispanic and Asian individuals, and people who inject drugs.

Abacavir/dolutegravir/lamivudine is a fixed-dose combination containing two nucleoside reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitor (INSTI).

Patients who were vaccinated and reinfected showed symptoms of few lesions, little mucosal disease, and minimal analgesia requirements.